Critical appraisal of trastuzumab in treatment of advanced stomach cancer

References

• American Cancer SocietyCancer Facts and Figures 2010Atlanta, GAAmerican Cancer Society2010
   Google Scholar
• SuganoKGastric cancer: Pathogenesis, screening, and treatmentGastrointest Endosc Clin N Am200818351352218674700
   PubMedGoogle Scholar
• InoueMTsuganeSEpidemiology of gastric cancer in JapanPostgrad Med J20058195741942415998815
   PubMed Web of Science ®Google Scholar
• FoukakisTLundellLGubanskiMAdvances in the treatment of patients with gastric adenocarcinomaActa Oncol200746327728517450463
   PubMed Web of Science ®Google Scholar
• MuradAMSantiagoFFPetroianuAModified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerCancer199372137418508427
   PubMed Web of Science ®Google Scholar
• PyrhönenSKuitunenTNyandotoPRandomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBr J Cancer19957115875917533517
   PubMed Web of Science ®Google Scholar
• GlimeliusBEkstromKHoffmanKRandomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnn Oncol1997821631689093725
   PubMed Web of Science ®Google Scholar
• JanungerKGHafströmLGlimeliusBChemotherapy in gastric cancer: A review and updated meta-analysisEur J Surg20021681159760812699095
   PubMedGoogle Scholar
• WagnerADGrotheWHaertingJChemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate dataJ Clin Oncol200624182903290916782930
   PubMed Web of Science ®Google Scholar
• RossPNicolsonMCunninghamDProspective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancerJ Clin Oncol20022081996200411956258
   PubMed Web of Science ®Google Scholar
• CunninghamDStarlingNRaoSUpper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United KingdomCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med20083581364618172173
   PubMed Web of Science ®Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A Report of the V325 Study GroupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• AjaniJAMoiseyenkoVMTjulandinSClinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study GroupJ Clin Oncol200725223205320917664467
   PubMed Web of Science ®Google Scholar
• BoucheORaoulJLBonnetainFRandomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study – FFCD 9803J Clin Oncol200422214319432815514373
   PubMed Web of Science ®Google Scholar
• MoehlerMEimermacherASieblerJRandomized phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancerBr J Cancer200592122122212815942629
   PubMed Web of Science ®Google Scholar
• DankMZaluskiJValvereVRandomized phase III trial of irinotecan (CPT 11) 5-FU/folinic acid (FA) vs CDDP–5-FU in first line advanced gastric cancer patientsJ Clin Oncol200523Suppl 16S4003
   PubMedGoogle Scholar
• BokuNYamamotoSShiraoKRandomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)J Clin Oncol200725Suppl 18 SLBA4513T.
   Google Scholar
• ImamuraHIIishiHTsuburayaARandomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002)Poster A5 presented at the ASCO Gastrointestinal Cancers SymposiumSan Francisco, CAJanuary 15–17, 2008
   Google Scholar
• KoizumiWNaraharaHHaraTS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trialLancet Oncol20089321522118282805
   PubMed Web of Science ®Google Scholar
• WagnerADUnerzagtSGrotheWNovel chemotherapy combinations in advanced gastric cancer: An updated meta-analysisAnn Oncol201021Suppl 8S740
   Google Scholar
• GuimbaudRLouvetCBonnetainFFinal results of the intergroup FFCD-GERCOR-FNCLCC 03-07 phase III study comparing two sequences of chemotherapy in advanced gastric cancersAnn Oncol201021Suppl 8S8010
   Google Scholar
• Thuss-PatiencePCKretzschmarADeistTIrinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)J Clin Oncol200927Suppl 5S4540
   Google Scholar
• ShimoyamaRYasuiHBokuNWeekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatinGastric Cancer200912420621120047125
   PubMed Web of Science ®Google Scholar
• TakahariDShimadaYTakeshitaSSecond-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancerGastric Cancer201013318619020820988
   PubMed Web of Science ®Google Scholar
• WilsonDHillerLGehJIReview of second-line chemotherapy for advanced gastric adenocarcinomaClin Oncol (R Coll Radiol)2005172819015830569
   PubMed Web of Science ®Google Scholar
• BokuNChemotherapy for metastatic gastric cancer in JapanInt J Clin Oncol200813648348719093174
   PubMed Web of Science ®Google Scholar
• BangYJKangYKKangWKPhase II study of sunitinib as second-line treatment for advanced gastric cancerInvest New Drugs2010512 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• YoonDHRyu1MLeeJPhase II study of everolimus in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinumAnn Oncol201021Suppl 8S725
   Google Scholar
• TebbuttNCSourjinaTStricklandAHATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer – final results of a multicentre phase II trial by the AGITGJ Clin Oncol200826Suppl 20S15554
   Google Scholar
• ArkenauHTGastric cancer in the era of molecularly targeted agents: current drug development strategiesJ Cancer Res Clin Oncol2009135285586619363621
   PubMed Web of Science ®Google Scholar
• OhtsuAChemotherapy for metastatic gastric cancer: Past, present, and futureJ Gastroenterol200843425626418458840
   PubMed Web of Science ®Google Scholar
• ShahMARamanathanRKIlsonDHMulticenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol200624335201520617114652
   PubMed Web of Science ®Google Scholar
• EnzingerPCFidiasPMeyerhardtJPhase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancerPoster A68 presented at the ASCO Gastrointestinal Cancers SymposiumSan Francisco, CAJanuary 26–28, 2006
   Google Scholar
• CohenuramMKLacyJFOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal (E), gastroesophageal (GE), and gastric (G) adenocarcinoma: A single institution’s initial clinical experiencePoster A74 presented at the ASCO Gastrointestinal Cancers SymposiumSan Francisco, CAJanuary 15–17, 2008
   Google Scholar
• HammadNPhilipPAShieldsAFA phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancerPoster A30 presented at the ASCO Gastrointestinal Cancers SymposiumSan Francisco, CAJanuary 15–17, 2008
   Google Scholar
• BangYJKangYKangWSunitinib as second line treatment for advanced gastric cancer: Preliminary results from a phase II studyJ Clin Oncol200725Suppl 18S4603
   PubMedGoogle Scholar
• ParkSRLeeKOhDSunitinib (su) with cisplatin (p) and capecitabine (x) or oxaliplatin (o) and x (xelox) in advanced gastric cancer (gc) – a phase I, dose-finding studyAnn Oncol201021Suppl 8S815
   PubMedGoogle Scholar
• MuroKMiyataYLiMWatanabeKBokuNCisplatin (P) in patients (pts) with advanced or metastatic gastric cancer (CG)Ann Oncol201021Suppl 8S816
   Google Scholar
• Gomez-MartinCGil-MartinMMontagutCA phase I, dose-finding study of sunitinib (su) in combination with cisplatin (p) and 5-fluorouracil (5-fu) in patients (pts) with advanced gastric cancer (gc)Ann Oncol201021Suppl 8S818
   Google Scholar
• SunWPowellMEO’DwyerPPhase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203J Clin Oncol201028182947295120458043
   PubMed Web of Science ®Google Scholar
• SteinAAl-BatranSEArnoldDCetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancerPoster A47 presented at the ASCO Gastrointestinal Cancers SymposiumSan Francisco, CAJanuary 15–17, 2008
   Google Scholar
• PintoCDi FabioFSienaSPhase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)Ann Oncol200718351051717164226
   PubMed Web of Science ®Google Scholar
• LordickFLuberBLorenzenSCetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Br J Cancer2010102350050520068568
   PubMed Web of Science ®Google Scholar
• KimCLeeJLRyuMHA prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancerInvest New Drugs2009129 [Epub ahead of print].
   Web of Science ®Google Scholar
• PintoCDi FabioFBaroneCPhase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)Br J Cancer200910181261126819773760
   PubMed Web of Science ®Google Scholar
• RaoSStarlingNCunninghamDMatuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II studyAnn Oncol201021112213221920497967
   PubMed Web of Science ®Google Scholar
• DragovichTMcCoySFenoglio-PreiserCSWOG 0127 phase II trial of erlotinib in GEJ and gastric adenocarcinomaJ Clin Oncol200624304922492717050876
   PubMed Web of Science ®Google Scholar
• DoiTKoizumiWSienaSEfficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancerProc Am Soc Clin Oncol200322 Abstr 1036.
   Google Scholar
• IqbalSGoldmanBLenzHJA phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancerJ Clin Oncol200725Suppl 8S4621
   Google Scholar
• LenzHZhangWKemnerAMLapatinib 1 capecitabine in advanced gastric cancer: An open-label phase II study of non ERBB2-targeted diseaseAnn Oncol201021Suppl 8S817
   Google Scholar
• OkinesAFAshleySECunninghamDEpirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trialJ Clin Oncol201028253945395020679619
   PubMed Web of Science ®Google Scholar
• RaoSStarlingNCunninghamDPhase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerBr J Cancer200899686887419238629
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMNovel anticancer targets: Revisiting ERBB2 and discovering ERB3Nat Rev Cancer20099746347519536107
   PubMed Web of Science ®Google Scholar
• HallaPSCameronDACurrent perspective – trastuzumabEur J Cancer2009451121819042123
   PubMed Web of Science ®Google Scholar
• CarterPPrestaLGormanCMHumanization of an anti-p185HER2 antibody for human cancer therapyProc Natl Acad Sci U S A19928910428542891350088
   PubMed Web of Science ®Google Scholar
• ValabregaGMontemurroFAgliettaMTrastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancerAnn Oncol200718697798417229773
   PubMed Web of Science ®Google Scholar
• TreishISchwartzRLindleyCPharmacology and therapeutic use of trastuzumab in breast cancerAm J Health Syst Pharm200057222063207611098307
   PubMed Web of Science ®Google Scholar
• BrunoRWashingtonCBLuJFPopulation pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancerCancer Chemother Pharmacol200556436136915868146
   PubMed Web of Science ®Google Scholar
• MarxAHTharunLMuthJHER-2 amplification is highly homogenous in gastric cancerHum Pathol200940676977719269014
   PubMed Web of Science ®Google Scholar
• Barros-SilvaJDLeitãoDAfonsoLAssociation of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patientsBr J Cancer2009100348749319156142
   PubMed Web of Science ®Google Scholar
• KimMAJungEJLeeHSEvaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reactionHum Pathol20073891386139317555797
   PubMed Web of Science ®Google Scholar
• TannerMHollmenMJunttilaTTAmplification of HER-2 in gastric carcinoma: Association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnn Oncol200516227327815668283
   PubMed Web of Science ®Google Scholar
• YanoTDoiTOhtsuAComparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancerOncol Rep2006151657116328035
   PubMed Web of Science ®Google Scholar
• YuGZChenYWangJJOverexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significanceJ Cancer Res Clin Oncol2009135101331133919337752
   PubMed Web of Science ®Google Scholar
• BangYChungHXuJPathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trialJ Clin Oncol200927Suppl 15S4556
   Web of Science ®Google Scholar
• GongSJJinCJRhaSYGrowth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell linesCancer Lett2004214221522415363548
   PubMed Web of Science ®Google Scholar
• Cortés-FunesHRiveraFAlésIPhase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplificationJ Clin Oncol200725Suppl 18S4613
   Web of Science ®Google Scholar
• EgamberdievDMDjuraevMDTuydjanovaKNematovONOur experience in the use of trastuzumab in patients with advanced stomach cancerAnn Oncol201021Suppl 8S839
   Google Scholar
• Van CutsemEKangYChungHToGA Trial InvestigatorsTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med20073571395117611206
   PubMed Web of Science ®Google Scholar
• SeidmanAHudisCPierriMKCardiac dysfunction in the trastuzumab clinical trials experienceJ Clin Oncol20022051215122111870163
   PubMed Web of Science ®Google Scholar
• GonzálezVSalgueiroEJimenoFJPost-marketing safety of antineoplasic MAb: Rituximab and trastuzumabPharmacoepidemiol Drug Saf200817771472118340626
   PubMed Web of Science ®Google Scholar
• OsobaDSlamonDJBurchmoreMMurphyMEffects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancerJ Clin Oncol200220143106311312118024
   PubMed Web of Science ®Google Scholar
• RugoHBrammerMZhangFLallaDEffect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: Data from three clinical trialsClin Breast Cancer201010428829320705561
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMPressMA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analysesBreast Cancer Res Treat2008112353354318188694
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerNew Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar